evoke semaglutide trial and evoke+: design of two large‐scale, double‐blind, placebo‐controlled, phase 3 studies evaluating the neuroprotective effects of in early Alzheimer's disease - Atri - 2022 - Alzheimer's & Dementia Semaglutide's Setback in Alzheimer Disease

We do not offer and would never undergo such unsafe technologies

On the other hand, compounded drugs are not subject to the same kind of regulation and do not require FDA approval

It should always be used as part of a medically-overseen plan, and supports steady progress when used alongside healthy lifestyle changes

PlexusDx requires a health intake form and prescriber consultation before dispensing, ensuring safety screening

Prescribing information (Amneal Pharmaceuticals, 2025)

The FDA warning applies only to medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2), which are different from common thyroid cancers